MAPK14 and neoplasm: Our experimental data support the role of p38 inhibitors as sensitizers for cisplatin therapy and suggest ralimetinib as a potential co-treatment to standard RCT for patients with significant Slug immunohistochemical positivity or pEMT tumor profile.